Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08049820 formulation comparison in healthy volunteers
NCT07172321Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of PF-08049820 in atopic dermatitis (AD) (5 arms), sponsored by Pfizer. Primary endpoints: Area Under the Concentration Versus Time Curve at 72 hours and Maximum Concentration at 72 hours. Started Sep 2025; status: completed.
02
Drugs
PF-08049820
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07172321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07172321.